BRAIN Biotech AG
XETRA:BNN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.445
4.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
BRAIN Biotech AG
BRAIN Biotech AG
Cost of Revenue
BRAIN Biotech AG
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BRAIN Biotech AG
XETRA:BNN
|
Cost of Revenue
-€24.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Wacker Chemie AG
XETRA:WCH
|
Cost of Revenue
-€6.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-5%
|
|
|
Evonik Industries AG
XETRA:EVK
|
Cost of Revenue
-€10.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Covestro AG
XETRA:1COV
|
Cost of Revenue
-€11.9B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
AlzChem Group AG
XETRA:ACT
|
Cost of Revenue
-€232.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Symrise AG
XETRA:SY1
|
Cost of Revenue
-€3.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
BRAIN Biotech AG
Glance View
BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 293 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
See Also
What is BRAIN Biotech AG's Cost of Revenue?
Cost of Revenue
-24.4m
EUR
Based on the financial report for Jun 30, 2024, BRAIN Biotech AG's Cost of Revenue amounts to -24.4m EUR.
What is BRAIN Biotech AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
0%
Over the last year, the Cost of Revenue growth was 1%. The average annual Cost of Revenue growth rates for BRAIN Biotech AG have been -13% over the past three years .
You don't have any saved screeners yet
